Adipocytokines and ghrelin level of bipolar patients from manic episode to euthymic episode

References

• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–552.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Danilewitz M, Liauw S, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010;126:366–387.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, Basile VS, et al. Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol. 2003;23:323–327.
   PubMed Web of Science ®Google Scholar
• Wysokiński A, Sobów T. Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine. Nord J Psychiatry. 2016;70:156–160.
   PubMed Web of Science ®Google Scholar
• Morriss R, Mohammed FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol. 2005;19:94–101.
   PubMed Web of Science ®Google Scholar
• Soczynska JK, Kennedy SH, Woldeyohannes HO, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med. 2011;13:93–116.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.
   PubMed Web of Science ®Google Scholar
• Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763–770.
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282:1568–1575.
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312.
   PubMed Web of Science ®Google Scholar
• Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulationin obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744–747.
   PubMed Web of Science ®Google Scholar
• Qatanani M, Szwergold NR, Greaves DR, et al. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest. 2009;119:531–539.
   PubMed Web of Science ®Google Scholar
• Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–981.
   PubMed Web of Science ®Google Scholar
• Rasouli N, Kern PA. Adipocytokines and the Metabolic Complicationsof Obesity. J Clin Endocrinol Metab. 2008;93:64–73.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–1295.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003;14:561–566.
   PubMed Web of Science ®Google Scholar
• Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin--a hormone with multiple functions. Front Neuroendocrinol. 2004;25:27–68.
   PubMed Web of Science ®Google Scholar
• Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–709.
   PubMed Web of Science ®Google Scholar
• Abizaid A, Liu ZW, Andrews ZB, et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest. 2006;116:3229–3239.
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Rocha DQC, McIntyre RS, et al. Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. J Psychiatr Res. 2014;59:28–37.
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
   PubMed Web of Science ®Google Scholar
• First MB, Robert L, Spitzer RL, et al. Structured clinical interview for DSM-IV axis I disorders (SCID-I). Washington (DC): American Psychiatric Press; 1997.
   Google Scholar
• Spitzer RL, Williams JBW, Gibbon M, et al. Manual for the structured clinical interview for DSM-III-R personality disorders. Washington (DC): American Psychiatric Press; 1990.
   Google Scholar
• Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148:161–169.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology. 2003;46:176–179.
   Web of Science ®Google Scholar
• Gergerlioglu HS, Savas HA, Celik A, et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology. 2006;53:108–112.
   PubMed Web of Science ®Google Scholar
• Tsai SY, Chung KH, Wu JY, et al. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136:110–116.
   PubMed Web of Science ®Google Scholar
• Barbosa IG, Rocha NP, de Miranda AS, et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res. 2012;46:389–393.
   PubMed Web of Science ®Google Scholar
• Hommel JD, Trinko R, Sears RM, et al. Leptin receptor signaling in midbrain dopamine neurons regulates feding. Neuron. 2006;51:801–810.
   PubMed Web of Science ®Google Scholar
• Matheny M, Shapiro A, Tumer N, et al. Region-specific diet-induced and leptin-induced cellular leptin resistance includes the ventral tegmental area in rats. Neuropharmacology. 2011;60:480–487.
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804–817.
   PubMed Web of Science ®Google Scholar
• Elmslie JL, Porter RJ, Joyce PR, et al. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry. 2009;43:53–60.
   PubMed Web of Science ®Google Scholar
• Hung YJ, Hsieh CH, Chen YJ, et al. Insulin sensitivity, pro inflammatory markers and adiponectin in young males with different subtypes of depressive disorder. Clin Endocrinol. 2007;67:784–789.
   PubMed Web of Science ®Google Scholar
• Soeiro-de-Souza ME, Gold PW, Brunoni AR, et al. Lithium deecreases plasma adiponectin levels in bipolar depression. Neurosci Lett. 2014;564:111–114.
   PubMed Web of Science ®Google Scholar
• Greco R, Latini G, Chiarelli F, et al. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology. 2005;65:1808–1809.
   PubMed Web of Science ®Google Scholar
• Brunetti L, Orlando G, Recinella L, et al. Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. Eur J Pharmacol. 2004;493:41–44.
   PubMed Web of Science ®Google Scholar
• Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–419.
   PubMed Web of Science ®Google Scholar
• Shin AC, Zheng H, Berthoud HR. An expanded view of energy homeostasis: neural integration of metabolic, cognitive and emotional drives to eat. Physiol Behav. 2009;97:572–580.
   PubMed Web of Science ®Google Scholar
• Stip E, Lungu OV, Anselmo K, et al. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry. 2012;2:e128.
   PubMed Web of Science ®Google Scholar
• Hegedűs C, Kovács D, Kiss R, et al. Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats. J Psychopharmacol. 2015;29:1271–1279.
   PubMed Web of Science ®Google Scholar
• Tagami K, Kashiwase Y, Yokoyama A, et al. The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: an in vitro study with cells expressing cloned human growth hormone secretagogue receptor. Neuropeptides. 2016;58:98–101.
   Web of Science ®Google Scholar
• Sagud M, Mihaljevic-Peles A, Pivac N, et al. Lipid levels in female patients with affective disorders. Psychiatry Res. 2009;168:218–221.
   PubMed Web of Science ®Google Scholar
• Vuksan-Ćusa B, Marčinko D, Nađ S, et al. Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:109–112.
   PubMed Web of Science ®Google Scholar
• Sobczak S, Honig A, Christophe A, et al. Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acidsin first-degree relatives of bipolar patients. Psychol Med. 2004;34:103–112.
   PubMed Web of Science ®Google Scholar
• Cardenas J, Frye MA, Marusak SL, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106:91–97.
   PubMed Web of Science ®Google Scholar
• Chang HH, Yang YK, Gean PW, et al. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord. 2010;124:319–323.
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10:788–797.
   PubMed Web of Science ®Google Scholar
• Maina G, Salvi V, Vitalucci A, et al. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008;110:149–155.
   PubMed Web of Science ®Google Scholar
• Peña R, Marquina D, Serrano A, et al. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment. Schizophr Res. 2008;106:315–319.
   PubMed Web of Science ®Google Scholar